Background: Heart failure (HF) and cancer are currently two leading causes of mortality, and 30 sometimes coexist. However, the relationship between them is not completely elucidated. We 31 aimed to investigate whether patients with HF are predisposed to cancer development using 32 the large Korean National Health Insurance claims database. 33 Methods and findings: This study included 128,441 HF patients without a history of cancer 34 and 642,205 age-and sex-matched individuals with no history of cancer and HF between 1 35 January 2010 and 31 December 2015. During a median follow-up of 4.06 years, 11,808 36 patients from the HF group and 40,805 participants from the control were newly diagnosed 37 with cancer (cumulative incidence, 9.2% vs. 6.4%, p<0.0001). Patients with HF presented a 38 higher risk for cancer development compared to controls in multivariable Cox analysis 39 (hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.61 -1.68). The increased risk was 40 consistent for all site-specific cancers. To minimize potential surveillance bias, additional 41
INTRODUCTION 8 141 development. The multivariable Cox models were adjusted for age, sex, income, diabetes 142 mellitus, smoking, alcohol consumption, and body mass index. The adjusted hazard ratio 143 (HR) was also calculated for the pre-specified subgroups (according to age, and the status of 144 income, smoking, and drinking). The risk of cancer development in each site-specific cancer 145 was expressed as HR with the corresponding 95% confidence interval (CI) in univariable and 146 multivariable analyses. 147 To avoid potential surveillance bias, a sensitivity analysis was additionally 148 performed by eliminating patients who were newly diagnosed with cancer within the initial 2 149 years of HF diagnosis, as well as those followed for less than 2 years (i.e. 2-year lag 150 analysis). The same statistical analyses were repeated in this 2-year lag cohort. SAS software 151 version 9.4 (SAS, Cary, NC, USA) was used in all statistical analyses, and p values <0.05 152 were considered statistically significant. 
RESULTS

155
Study population 156 In the present cohort (n = 770,646; mean age, 67.1 years; men, 51.9%), patients with 157 HF (n=128,441) were compared with age-and sex-matched controls (n = 642,205) . Table 1 158 summarizes the baseline characteristics of the study population. Briefly, patients with HF 159 were more likely to be obese, to have a smoking history, and comorbidities such as diabetes 160 mellitus, hypertension, and dyslipidemia (all p <0.0001), whereas alcohol consumption was 161 more prevalent in the controls (p <0.0001). Table 2) . The cumulative incidence of 176 cancer in the HF group was higher than that of the control group (p <0.0001) (Fig 2A) . The
177
higher cancer incidence among the HF group was consistently observed for all site-specific 178 cancers ( Table 2) . The cumulative incidence of the four most common site-specific cancers is 179 shown in Fig 3A. Of note, the incidence rate of overall cancer was markedly increased in the 180 HF group for the first 2 years of HF diagnosis (Fig 2A) . The same trend was consistently 181 observed for all major site-specific cancers (Fig 3A) . the HF group in both the unadjusted and multivariable-adjusted analysis (Table 3) , with the 214 highest HRs noted for hematologic and lung malignancy. This association remained constant 215 in the separate analysis by sex except for skin cancer (S2 Table) . The adjusted risk of overall 216 cancer was also significantly increased in all pre-specified subgroups (S1 Fig) . hypertension, and dyslipidemia, except for alcohol consumption (S3 Table) . 233 The mean follow-up period of the 2-year lag cohort was 4.48 years (interquartile 234 range, 3.17 -5.97 years). The number of cancer diagnoses and incidence rate per 1,000 235 person-year in the 2-year lag cohort are shown in Table 2 . The cumulative incidence of 236 overall cancers in the 2-year lag cohort was still significantly higher in the HF group (p 237 =0.0001), although the gap between the two groups became smaller than that analyzed in the 238 original cohort (Fig 2B) . Cox proportional hazard analysis showed that the HF group 239 demonstrated a significantly increased risk of overall cancers in both the unadjusted (HR 240 1.11, 95% CI 1.08 -1.15; p <0.0001) and multivariable-adjusted analysis (HR 1.09, 95% CI 241 1.05 -1.13; p <0.0001), with a smaller HR compared to that of no lag analysis ( patients with HF than that of the general population, which implies that physicians are more 318 encouraged to keep the possibility of coexisting malignancy in mind, and to perform active 319 cancer screening in these population at risk. In particular, the surveillance could be targeted
